| 1/2 - Pediatric Prehospital Airway Resuscitation Trial |
Cooperative Agreement |
116,052.00 |
Research |
Joshua Gaither |
Dept of Emergency Medicine |
03/2024 |
| 1/2 Trauma Resuscitation with Group O Whole Blood Or Products (TROOP) Trial |
Cooperative Agreement |
267,876.00 |
Research |
Bellal Joseph |
Surgery |
03/2024 |
| A Double-Blind, Active-Controlled, Multiple-Ascending Dose Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeru |
Contract |
306,429.52 |
Clinical Trial |
Cori Daines |
Asthma/Airway Disease Rsch Ctr |
01/2024 |
| A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE) |
Contract |
749,783.32 |
Clinical Trial |
David Labiner |
Neurology |
11/2023 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck S |
Contract |
119,770.80 |
Clinical Trial |
Ricklie Julian |
Cancer Center Division |
02/2024 |
| A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer |
Contract |
502,760.72 |
Clinical Trial |
Aaron Scott |
Cancer Center Division |
03/2024 |
| A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers |
Contract |
509,763.60 |
Clinical Trial |
Rachna Shroff |
Cancer Center Division |
12/2023 |
| A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension |
Contract |
235,166.76 |
Clinical Trial |
Nafis Shamsid-Deen |
COM Phx Internal Medicine |
11/2023 |
| A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALT-100 in Patients With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) |
Contract |
369,191.00 |
Clinical Trial |
Zachary Hernandez |
COM Phx Internal Medicine |
11/2023 |
| A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke Who Ar |
Contract |
470,257.20 |
Clinical Trial |
Firas Kaddouh |
Neurology |
03/2024 |
| A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom |
Contract |
1,246,360.61 |
Clinical Trial |
Abhijeet Kumar |
Cancer Center Division |
02/2024 |
| A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xla Inhibitor, for Stroke Prevention After an Acute Is |
Contract |
341,296.28 |
Clinical Trial |
Firas Kaddouh |
Neurology |
12/2023 |
| A Phase 3, Randomized, Open-label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-cell Lymphoma (DLB |
Contract |
1,097,975.93 |
Clinical Trial |
Abhijeet Kumar |
Cancer Center Division |
11/2023 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have |
Contract |
964,023.30 |
Clinical Trial |
Daniel Butler |
Medicine |
01/2024 |
| A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clin |
Contract |
169,895.50 |
Clinical Trial |
Sasha Taleban |
Medicine |
11/2023 |
| A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gen |
Contract |
1,091,512.00 |
Clinical Trial |
Paul Larson |
Neurosurgery |
01/2024 |
| A Phase III, Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infec |
Contract |
1,286,672.52 |
Clinical Trial |
Christian Bime |
Medicine |
11/2023 |
| A Randomized Controlled Trial to Evaluate the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose at Increased Risk of Liver Injury |
Contract |
274,224.40 |
Clinical Trial |
Farshad Shirazi |
Dept of Emergency Medicine |
01/2024 |
| A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women with ER+/HER2- Breast Cancer |
Contract |
300,639.36 |
Clinical Trial |
Sima Ehsani Chimeh |
Cancer Center Division |
03/2024 |
| A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pln-74809 (Bexotegrast) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF) |
Contract |
221,588.92 |
Clinical Trial |
Sachin Chaudhary |
Medicine |
03/2024 |
